Start Planning for 2022 Now: Model Your Future with the Q4 2022 Memorandum

Sanofi proudly announced today that the Memorandum for Q4 2022, for modelling purposes, is now available for investors to access on the company’s website. This is a great opportunity to gain insight into their current financial performance and to plan for the future.

Sanofi will be unveiling its fourth-quarter 2022 results on February 3, 2023, and to help you prepare for the financial modelling of the Group’s quarterly results, we have created a document that includes a reminder on various non-comparable items and exclusivity losses, foreign currency impact, and share count. Get ready to see a comprehensive overview of Sanofi’s fourth-quarter performance.

At our innovative global healthcare company, we pursue miracles of science to make a positive impact on people’s lives. Our dedicated team across 100 countries is devoted to breaking barriers in medicine, turning the impossible into the possible. We provide life-saving treatments and vaccines to millions of people worldwide, all while upholding sustainability and social responsibility. Let us help you make a positive difference in the world.

Sanofi Forward-Looking Statements

Sanofi is committed to bringing innovative treatments to patients and is focused on delivering long-term value for our shareholders. However, the development and commercial success of our product candidates is subject to various risks and uncertainties, including approvals from regulatory authorities such as the FDA or EMA, trends in exchange rates and prevailing interest rates, and the impact of the COVID-19 pandemic on us, our customers, suppliers, vendors, and other business partners. We are aware of the risks associated with our forward-looking statements and are making every effort to ensure that our plans remain on track.

Leave a Comment